More on ACRS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.12 |
|
|||
| Open | $3.02 | ||||
| 52 Wk High | $33.88 | ||||
| 52 Wk Low | $14.12 | ||||
| Day High | $3.13 | ||||
| Day Low | $3.00 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,209,821 | ||||
- Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Balthaser Kevin
- Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference
- Aclaris Therapeutis (ACRS) PT Raised to $3 at Stifel
- Form 10-K Aclaris Therapeutics, For: Dec 31
- Aclaris Therapeutics (ACRS) Misses Q4 EPS by 1c
- Form 8-K Aclaris Therapeutics, For: Feb 26
- Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Aclaris Therapeutics begins phase 1b trial of ATI-052 in asthma patients
- Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
- Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: BML Investment Partners, L.P.
Entities mentioned with ACRS
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- Jefferies & Co | View Related Stories »
- William Blair | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
